The delisting risk is materially resolved by the $350M financing, but Nasdaq has not yet confirmed compliance and will re-evaluate at the next annual report. Monitor for Nasdaq's formal confirmation and the outcome of the November 10 hearing, which the company expects to be cancelled. The large equity raise also introduces significant dilution — watch for stockholder approval of Series B and C preferred conversion and the related authorized share increase.
Price Chart
Executive Summary
Alaunos Therapeutics filed this 8-K to report that, following its October 13, 2026 acquisition of Velaris Therapeutics and a concurrent private placement raising approximately $350.0 million in gross proceeds, it believes it has regained compliance with Nasdaq's $2.5 million stockholders' equity continued listing requirement. The company had been facing delisting since April 2026 for failing to meet the equity standard, and a Nasdaq hearing was scheduled for November 10, 2026. While the financing resolves the immediate delisting risk, Nasdaq has not yet confirmed compliance, and the company warns that if its next annual report does not evidence compliance, it may again face delisting.
Key Facts
- Company received Nasdaq deficiency notice on April 9, 2026 for failing to maintain minimum $2.5 million stockholders' equity (reported $2,153,000 as of Dec 31, 2025).
- On October 5, 2026, Nasdaq notified company its securities were subject to delisting unless a hearing was requested; hearing scheduled for November 10, 2026.
- On October 13, 2026, company completed acquisition of Velaris Therapeutics, Inc. and entered a private placement financing.
- Financing closed October 14, 2026: 687,789 common shares at $1.4357/share and 243,063 Series C Preferred shares at $1,435.70/share, raising aggregate gross proceeds of approximately $350.0 million.
- Fairmount Healthcare Fund II provided an irrevocable waiver of the cash settlement right on 6,268 Series C Preferred shares (value ~$9.0 million), allowing those shares to count toward permanent equity.
- Company believes it has regained compliance with the stockholders' equity requirement as of this filing.
- Nasdaq will continue to monitor compliance; if the Annual Report for FY ending Dec 31, 2026 does not evidence compliance, the company may be subject to delisting.
- No assurance that Nasdaq will concur with the company's determination or as to timing of confirmation.
Financial Impact
Company raised approximately $350.0 million in gross proceeds from a private placement, which it believes brings stockholders' equity above the $2.5 million minimum required for continued listing.
Risk Factors
- Nasdaq may not concur with the company's determination that it has regained compliance.
- If the next annual report does not show compliance, delisting proceedings could resume.
- Preliminary accounting classification of preferred stock may change upon audit review.
- Stockholder approval of preferred conversion and authorized share increase is required but not yet obtained.
- Operating losses and transaction costs could erode stockholders' equity going forward.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-427890 |
| Document: 0001193125-26-427890-index-headers.html | 0001193125-26-427890 |
| Document: 0001193125-26-427890-index.html | 0001193125-26-427890 |
| Document: 0001193125-26-427890.txt | 0001193125-26-427890 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.39 | awaiting T+20 | — | $1.94 (−18.75%) |
Oct 21, 2026 5d ago | 8-K | $3.04 | awaiting T+20 | — | $1.94 (−36.18%) |
Oct 15, 2026 11d ago | SC 13D/A | $2.63 | awaiting T+20 | — | $1.94 (−26.24%) |
Oct 15, 2026 11d ago | SC 13D | $2.63 | awaiting T+20 | — | $1.94 (−26.24%) |
Oct 13, 2026 14d ago | Press Release | $3.03 | awaiting T+20 | — | $1.94 (−35.97%) |
Oct 13, 2026 14d ago | 8-K | $3.03 | awaiting T+20 | — | $1.94 (−35.97%) |
Oct 9, 2026 17d ago | 8-K | $1.05 | awaiting T+20 | — | $1.94 (−84.76%) |
Sep 18, 2026 5w ago | Press Release | $1.20 $2.63 | ▼ −119.17% | ▼ −118.96% | $1.94 (−61.67%) |
Sep 16, 2026 5w ago | 8-K | $1.60 $2.18 | ▲ +36.25% | ▲ +34.79% | $1.94 (+21.25%) |
Jun 29, 2026 17w ago | 8-K | $2.37 $1.94 | ▼ −18.14% | ▼ −17.86% | $1.94 (−18.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers